PortalPublikationenNetwork meta-analysis comparing the efficacy of biologic tre...

Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis

Standard

Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. / Reich, Kristian; Conrad, Curdin; Kristensen, Lars Erik; Smith, Saxon D; Puig, Luis; Rich, Phoebe; Sapin, Christophe; Holzkaemper, Thorsten; Koppelhus, Uffe; Schuster, Christopher.

in: J DERMATOL TREAT, Jahrgang 33, Nr. 3, 05.2022, S. 1652-1660.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Reich, K, Conrad, C, Kristensen, LE, Smith, SD, Puig, L, Rich, P, Sapin, C, Holzkaemper, T, Koppelhus, U & Schuster, C 2022, 'Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis', J DERMATOL TREAT, Jg. 33, Nr. 3, S. 1652-1660. https://doi.org/10.1080/09546634.2021.1892024

APA

Reich, K., Conrad, C., Kristensen, L. E., Smith, S. D., Puig, L., Rich, P., Sapin, C., Holzkaemper, T., Koppelhus, U., & Schuster, C. (2022). Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J DERMATOL TREAT, 33(3), 1652-1660. https://doi.org/10.1080/09546634.2021.1892024

Vancouver

Reich K, Conrad C, Kristensen LE, Smith SD, Puig L, Rich P et al. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J DERMATOL TREAT. 2022 Mai;33(3):1652-1660. https://doi.org/10.1080/09546634.2021.1892024

Bibtex

@article{6547ba79ee5442da9ff856b24083aa69,
title = "Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis",
abstract = "BACKGROUND: Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics.OBJECTIVE: To evaluate the comparative efficacy of approved biologics in achieving complete resolution of NP at week 24‒26.METHODS: A network meta-analysis (NMA) was conducted to indirectly compare the efficacy of six biologics in achieving complete resolution of NP at week 24‒26 in patients with moderate-to-severe psoriasis and concomitant NP. Complete resolution of NP was defined as a score of zero on the Nail Psoriasis Severity Index (NAPSI), modified NAPSI (mNAPSI) or Physician's Global Assessment of Fingernails (PGA-F).RESULTS: The probability of achieving complete resolution of NP was highest for ixekizumab (46.5%; 95% credibility interval [CrI] 35.1‒58.0; Surface Under the Cumulative RAnking curve [SUCRA] 97%), followed by brodalumab (37.0%; 17.0‒61.0; 79%), adalimumab (28.3%; 24.4‒32.4; 62%), guselkumab (27.7%; 21.1‒35.1; 58%), ustekinumab (20.8%; 10.2‒35.2; 37%), and infliximab (0.8%; 0.0‒8.9; 17%).CONCLUSION: In patients with moderate-to-severe psoriasis and concomitant NP, ixekizumab has the greatest likelihood among approved biologics of achieving complete resolution of NP at week 24‒26. Findings should be interpreted carefully because of inherent study limitations.",
keywords = "Biological Products/therapeutic use, Humans, Nail Diseases/drug therapy, Network Meta-Analysis, Psoriasis/drug therapy, Severity of Illness Index, Treatment Outcome",
author = "Kristian Reich and Curdin Conrad and Kristensen, {Lars Erik} and Smith, {Saxon D} and Luis Puig and Phoebe Rich and Christophe Sapin and Thorsten Holzkaemper and Uffe Koppelhus and Christopher Schuster",
year = "2022",
month = may,
doi = "10.1080/09546634.2021.1892024",
language = "English",
volume = "33",
pages = "1652--1660",
journal = "J DERMATOL TREAT",
issn = "0954-6634",
publisher = "informa healthcare",
number = "3",

}

RIS

TY - JOUR

T1 - Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis

AU - Reich, Kristian

AU - Conrad, Curdin

AU - Kristensen, Lars Erik

AU - Smith, Saxon D

AU - Puig, Luis

AU - Rich, Phoebe

AU - Sapin, Christophe

AU - Holzkaemper, Thorsten

AU - Koppelhus, Uffe

AU - Schuster, Christopher

PY - 2022/5

Y1 - 2022/5

N2 - BACKGROUND: Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics.OBJECTIVE: To evaluate the comparative efficacy of approved biologics in achieving complete resolution of NP at week 24‒26.METHODS: A network meta-analysis (NMA) was conducted to indirectly compare the efficacy of six biologics in achieving complete resolution of NP at week 24‒26 in patients with moderate-to-severe psoriasis and concomitant NP. Complete resolution of NP was defined as a score of zero on the Nail Psoriasis Severity Index (NAPSI), modified NAPSI (mNAPSI) or Physician's Global Assessment of Fingernails (PGA-F).RESULTS: The probability of achieving complete resolution of NP was highest for ixekizumab (46.5%; 95% credibility interval [CrI] 35.1‒58.0; Surface Under the Cumulative RAnking curve [SUCRA] 97%), followed by brodalumab (37.0%; 17.0‒61.0; 79%), adalimumab (28.3%; 24.4‒32.4; 62%), guselkumab (27.7%; 21.1‒35.1; 58%), ustekinumab (20.8%; 10.2‒35.2; 37%), and infliximab (0.8%; 0.0‒8.9; 17%).CONCLUSION: In patients with moderate-to-severe psoriasis and concomitant NP, ixekizumab has the greatest likelihood among approved biologics of achieving complete resolution of NP at week 24‒26. Findings should be interpreted carefully because of inherent study limitations.

AB - BACKGROUND: Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics.OBJECTIVE: To evaluate the comparative efficacy of approved biologics in achieving complete resolution of NP at week 24‒26.METHODS: A network meta-analysis (NMA) was conducted to indirectly compare the efficacy of six biologics in achieving complete resolution of NP at week 24‒26 in patients with moderate-to-severe psoriasis and concomitant NP. Complete resolution of NP was defined as a score of zero on the Nail Psoriasis Severity Index (NAPSI), modified NAPSI (mNAPSI) or Physician's Global Assessment of Fingernails (PGA-F).RESULTS: The probability of achieving complete resolution of NP was highest for ixekizumab (46.5%; 95% credibility interval [CrI] 35.1‒58.0; Surface Under the Cumulative RAnking curve [SUCRA] 97%), followed by brodalumab (37.0%; 17.0‒61.0; 79%), adalimumab (28.3%; 24.4‒32.4; 62%), guselkumab (27.7%; 21.1‒35.1; 58%), ustekinumab (20.8%; 10.2‒35.2; 37%), and infliximab (0.8%; 0.0‒8.9; 17%).CONCLUSION: In patients with moderate-to-severe psoriasis and concomitant NP, ixekizumab has the greatest likelihood among approved biologics of achieving complete resolution of NP at week 24‒26. Findings should be interpreted carefully because of inherent study limitations.

KW - Biological Products/therapeutic use

KW - Humans

KW - Nail Diseases/drug therapy

KW - Network Meta-Analysis

KW - Psoriasis/drug therapy

KW - Severity of Illness Index

KW - Treatment Outcome

U2 - 10.1080/09546634.2021.1892024

DO - 10.1080/09546634.2021.1892024

M3 - SCORING: Journal article

C2 - 33641593

VL - 33

SP - 1652

EP - 1660

JO - J DERMATOL TREAT

JF - J DERMATOL TREAT

SN - 0954-6634

IS - 3

ER -